February 10, 2026 Sweden
Lilla lo?rdag – Diamyd Medical
During the weekly life science breakfast seminar “Lilla lördag”, Diamyd Medical’s CEO Ulf Hannelius addressed the topic Precision Immunotherapy in type 1 diabetes. The presentation included insights from the company’s ongoing Phase 3 clinical trial evaluating retogatein (rhGAD65), ahead of an interim readout expected in March 2026.
The event was recorded by Flemingsberg Science Foundation in Flemingsberg on February 5, 2026.
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.